BOSTON, Ma. – April 14, 2020 – Celero Systems, Inc., a life sciences company developing a revolutionary ingestible system to detect and reverse opioid overdose, today announced that they have licensed technology from Partners HealthCare Innovation and its affiliates, Massachusetts General Hospital, Brigham and Women’s Hospital, as well as from Massachusetts Institute of Technology to enhance the company’s ingestible technology platform.
The technology licensed by Celero Systems was developed from research on electronic sensing of physiologic and pathophysiologic parameters from within the gastrointestinal tract. As part of this agreement, the researchers who originally created the technology will work with Celero Systems as scientific advisors in development to further accelerate the investigation of these technologies.
“This collaboration with Partners Healthcare has enabled acceleration of Celero’s initial product development program in opioid overdose,” said Ben Pless, founder and CEO, Celero Systems. “With more than 190 deaths occurring daily in the United States due to drug overdoses, we have a strong commitment to bringing a new solution to address this epidemic.”
“No person should die from an opioid overdose,” said Sarah Wakeman, MD, medical director of the Massachusetts General Hospital Substance Use Disorder Initiative. “We are seeking effective tools that can help advance us toward that goal of zero deaths and allow us to better help patients with substance use disorder.”
About Celero Systems, Inc.
Celero Systems is a life sciences company focused on reducing opioid overdose mortality and injury by providing timely, autonomous, life-saving interventions. Celero is developing a revolutionary new ingestible system to automatically detect and reverse opioid overdose. The company is headquartered in the Boston, Massachusetts and led by a veteran team with deep healthcare and technology experience.
For more information, please visit celerosystems.com.